Sagent Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 244,750 183,615 152,405 74,056
Cost of Revenue 167,228 152,508 133,636 65,013
Gross Profit 77,522 31,107 18,769 9,043
Operating Expenses
Research and Development 20,275 17,136 12,763 11,223
Sales, General and Admin. 28,262 30,093 25,148 18,931
Non-Recurring Items - 708 - -
Other - - - -
Operating Income 31,380 (15,493) (21,673) (22,587)
Income From Continuing Operations
Add'l Income/Expense Items 39 243 (554) (779)
Earnings Before Interest and Tax 31,419 (15,250) (22,227) (23,366)
Interest Expense 930 1,567 4,195 1,129
Earnings Before Tax 30,489 (16,817) (26,422) (24,495)
Income Tax 895 - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary 2,395 1,337 (2,531) (1,476)
Net Income Cont. Operations 31,989 (15,480) (28,953) (25,971)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 29,594 (16,817) (26,422) (24,495)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 29,594 (16,817) (26,422) (24,495)